Skip to main content
Top
Published in: BMC Public Health 1/2013

Open Access 01-12-2013 | Research article

Prevalence and predictors of over-the-counter medication use among pregnant women: a cross-sectional study in the Netherlands

Authors: Gwenny MPJ Verstappen, Elise J Smolders, Janna M Munster, Jan G Aarnoudse, Eelko Hak

Published in: BMC Public Health | Issue 1/2013

Login to get access

Abstract

Background

Over-the-counter-medication (OTC-medication) use during pregnancy can be potentially harmful for the fetus. To successfully counsel the patient it is important to know if the patient is at risk. In this study possible predictors for OTC-medication use were identified and a model was designed to predict OTC-medication use during pregnancy.

Methods

We performed a post-hoc analysis on data collected for a clustered clinical trial to study a screening strategy for Query fever. Pregnant women under supervision of a midwife were eligible for inclusion. These women filled out questionnaires during their pregnancy and post-partum. These questionnaires were used to determine the prevalence and to select possible predictors for OTC-medication use. These predictors were included in a prediction model using multivariate analysis. The discrimination and calibration of the model were assessed with Receiver Operating Characteristic analysis and the Hosmer and Lemeshow test.

Results

Of the 1348 women enrolling in the clustered clinical trial, we included 1246 women in this analysis. The prevalence of OTC-medication use was 12.5%. The predictors for OTC-medication use in our cohort were: nulliparity, use of prescription medication, the presence of a comorbidity, Body Mass Index between 26 and 30 kg/m2 and General Practitioner visits. These predictors were used to design a prediction model for OTC-medication use. The area under the Receiver Operating Characteristic-curve of the prediction model was 0.667 (95% CI 0.620-0.714 P<0.001) and the predictive probabilities ranged from 6.6% to 57.4%. The Hosmer and Lemeshow goodness-of-fit test indicated good calibration of the model (P = 0.640).

Conclusion

It is possible to indicate women at risk for OTC-medication use during pregnancy, using five maternal characteristics that independently contribute to the prediction model. The predictors are easy to estimate and the model is easy to implement in daily practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Koren G, Florescu A, Moldovan Costei A, Boskovic R, More ME: Nonsteroidal Antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006, 40: 824-829. 10.1345/aph.1G428.CrossRefPubMed Koren G, Florescu A, Moldovan Costei A, Boskovic R, More ME: Nonsteroidal Antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006, 40: 824-829. 10.1345/aph.1G428.CrossRefPubMed
2.
go back to reference Nakhai-Pour HR, Broy P, Sheehy O, Bérard A: Use of nonaspirinnonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011, 183 (supl 15): 1713-1720. doi:10.1503/CMAJ.110454CrossRefPubMedPubMedCentral Nakhai-Pour HR, Broy P, Sheehy O, Bérard A: Use of nonaspirinnonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011, 183 (supl 15): 1713-1720. doi:10.1503/CMAJ.110454CrossRefPubMedPubMedCentral
3.
go back to reference WINAp Geneesmiddel Informatie: Standaarden voor Zelfzorg. 2008, Den Haag WINAp Geneesmiddel Informatie: Standaarden voor Zelfzorg. 2008, Den Haag
4.
go back to reference Glover DD, Amonkar M, Rybeck BF, Tracy TS: Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J ObstetGynecol. 2003, 188: 1039-1045. 10.1067/mob.2003.223.CrossRef Glover DD, Amonkar M, Rybeck BF, Tracy TS: Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J ObstetGynecol. 2003, 188: 1039-1045. 10.1067/mob.2003.223.CrossRef
5.
go back to reference Rubin JD, Ferencz D, Lofferedo C, The Balitmore-Washington infant study group: Use of prescription and non-prescription drugs in pregnancy. J ClinEpidemiol. 1993, 46: 581-589. 10.1016/0895-4356(93)90132-K. Rubin JD, Ferencz D, Lofferedo C, The Balitmore-Washington infant study group: Use of prescription and non-prescription drugs in pregnancy. J ClinEpidemiol. 1993, 46: 581-589. 10.1016/0895-4356(93)90132-K.
6.
go back to reference De Vigan C, De Walle HEK, Cordier S, Goujard J, Knill-Jones R, Aymé S, Calzolari E, Bianchi F: Therapeutic drug use during pregnancy: a comparison in four European countries. J ClinEpidemiol. 1999, 52: 977-982. 10.1016/S0895-4356(99)00091-8. De Vigan C, De Walle HEK, Cordier S, Goujard J, Knill-Jones R, Aymé S, Calzolari E, Bianchi F: Therapeutic drug use during pregnancy: a comparison in four European countries. J ClinEpidemiol. 1999, 52: 977-982. 10.1016/S0895-4356(99)00091-8.
7.
go back to reference Schirm E, Meijer WM, Tobi H, De Jong-van den Berg LTW: Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. Eur J ObstetGynecol and ReprodBiol. 2004, 114: 182-188. 10.1016/j.ejogrb.2003.10.024.CrossRef Schirm E, Meijer WM, Tobi H, De Jong-van den Berg LTW: Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. Eur J ObstetGynecol and ReprodBiol. 2004, 114: 182-188. 10.1016/j.ejogrb.2003.10.024.CrossRef
8.
go back to reference Munster JM, Leenders ACAP, van der Hoek W, Schneeberger PM, Rietveld A, Riphagen-Dalhuisen J, Stolk RP, Hamilton CJ, de Vries E, Meekelenkamp J, Lo-Ten-Foe JR, Timmer A, De Jong-van den Berg LTW, Aarnoudse JG, Hak E: Cost-effectiveness of a screening strategy for Q fever among pregnant women in risk areas: a clustered randomized controlled trail. BMC Womens Health. 2010, 10: 32-10.1186/1472-6874-10-32.CrossRefPubMedPubMedCentral Munster JM, Leenders ACAP, van der Hoek W, Schneeberger PM, Rietveld A, Riphagen-Dalhuisen J, Stolk RP, Hamilton CJ, de Vries E, Meekelenkamp J, Lo-Ten-Foe JR, Timmer A, De Jong-van den Berg LTW, Aarnoudse JG, Hak E: Cost-effectiveness of a screening strategy for Q fever among pregnant women in risk areas: a clustered randomized controlled trail. BMC Womens Health. 2010, 10: 32-10.1186/1472-6874-10-32.CrossRefPubMedPubMedCentral
9.
go back to reference WHO Collaborating Centre for Drug Statistics Methodology: ATC classification index with DDDs. 2011, Oslo WHO Collaborating Centre for Drug Statistics Methodology: ATC classification index with DDDs. 2011, Oslo
10.
go back to reference WINap Geneesmiddel Informatie en Wetenschapswinkel Groningen: Zelfzorgmedicijnen tijdens zwangerschap en borstvoeding; wat kan ik doen, wat mag ik slikken?. 2004, Groningen WINap Geneesmiddel Informatie en Wetenschapswinkel Groningen: Zelfzorgmedicijnen tijdens zwangerschap en borstvoeding; wat kan ik doen, wat mag ik slikken?. 2004, Groningen
11.
go back to reference Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG: Prognosis and prognostic research: what, why and how?. BMJ. 2009, 338: 1317-1320. 10.1136/bmj.b375.CrossRef Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG: Prognosis and prognostic research: what, why and how?. BMJ. 2009, 338: 1317-1320. 10.1136/bmj.b375.CrossRef
12.
go back to reference Werler MW, Mitchell AA, Hernandez-Diaz S, Honein MA: Use of over-the-counter medications during pregnancy. Am J ObstetGynecol. 2005, 193: 771-7. 10.1016/j.ajog.2005.02.100.CrossRef Werler MW, Mitchell AA, Hernandez-Diaz S, Honein MA: Use of over-the-counter medications during pregnancy. Am J ObstetGynecol. 2005, 193: 771-7. 10.1016/j.ajog.2005.02.100.CrossRef
13.
go back to reference Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ: Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf. 2010, 19: 408-417. 10.1002/pds.1906.PubMed Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ: Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf. 2010, 19: 408-417. 10.1002/pds.1906.PubMed
14.
go back to reference Bonassi S, Magnani M, Calvi A, Repetto E, Puglisi P, Pantarotto F, Lazzaroni F: Factors related to drug consumption during pregnancy. Acta Obstet Gynecol Scand. 1994, 73: 535-540. 10.3109/00016349409006269.CrossRefPubMed Bonassi S, Magnani M, Calvi A, Repetto E, Puglisi P, Pantarotto F, Lazzaroni F: Factors related to drug consumption during pregnancy. Acta Obstet Gynecol Scand. 1994, 73: 535-540. 10.3109/00016349409006269.CrossRefPubMed
15.
go back to reference Bercaw J, Maheshwari B, Sangi-Haghpeykar H: The use during pregnancy of prescription, over-the-counter, and alternative medications among Hispanic women. Birth. 2010, 37: 211-218. 10.1111/j.1523-536X.2010.00408.x.CrossRefPubMed Bercaw J, Maheshwari B, Sangi-Haghpeykar H: The use during pregnancy of prescription, over-the-counter, and alternative medications among Hispanic women. Birth. 2010, 37: 211-218. 10.1111/j.1523-536X.2010.00408.x.CrossRefPubMed
16.
go back to reference de Jong-van den Berg LTW, Waardenburg C: Geneesmiddelengebruik tijdens zwangerschap. 1991, Groningen: STYX de Jong-van den Berg LTW, Waardenburg C: Geneesmiddelengebruik tijdens zwangerschap. 1991, Groningen: STYX
Metadata
Title
Prevalence and predictors of over-the-counter medication use among pregnant women: a cross-sectional study in the Netherlands
Authors
Gwenny MPJ Verstappen
Elise J Smolders
Janna M Munster
Jan G Aarnoudse
Eelko Hak
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2013
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-13-185

Other articles of this Issue 1/2013

BMC Public Health 1/2013 Go to the issue